ASCO GU 2026

Combination is the way to go - but how to select?

Encouraging new data in Prostate cancer

Actinium radioligand therapy

Precision medicine for prostate cancer

New Mode of Action in mCRPC

T-Cell-Engager

Neoadjuvant therapy after molecular biopsy testing

T-cell engager - first in human

Radium-223 + Enzalutamid

PSA-dynamics in TALAPRO-2

EZH2 oral molecule to enhance ARPI

Patient Preferences for ARPI vs ADT in nmHSPC: A Global…

Prolonged PSA declines with normalization of…

Early SBRT shows safety, no added benefit

Adjuvant therapy for RCC: Progress made, key questions…

Treatment after immunotherapy in aRCC: always a complex…

HIF based combination are here to stay

New follow-up therapy with lenvatinib + belzutifan

Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab

Balancing efficacy and toxicity: the challenge in high…

Belzutifan + Lenvatinib: A New Second-Line Approach in…

Advances in the Adjuvant Treatment of RCC

Long‑term effects of adjuvant therapy

Upcoming new standard for adjuvant RCC

Combination therapy in adjuvant RCC

Real World Data - RCC

Tratamiento después de la inmunoterapia en el carcinoma…

The future is bright, but complex

Important steps towards biomarker driven treatment of…

Closing the gap for platin eligibility

EV+P new SOC in MIBC

ctDNA dynamics in the IMvigor011 trial

ctDNA testing: Who, how and how often?

Promising data - how to stratify the patients for the…

New machanism of action in pts with UC

MIBC - time for a historic paradigm shift?

New perioperative standard for MIBC

A new class of drug in luminal UC

ctDNA from plasma and urine in MIBC

Rethinking the use of HER2neu in routine clinical…

Urinary ctDNA vs. plasma ctDNA

Perioperative EV + P - the new standard?!

pCR in MIBC under EV + P

Une nouvelle classe de médicaments pour le carcinome…

Dinámica del ctDNA en el ensayo IMvigor011

EV + P : nouveau standard de traitement pour le TVIM